Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - KIAA1217 FGFR2 L550F |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - KIAA1217 FGFR2 L550F | cholangiocarcinoma | predicted - resistant | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-KIAA1217 fusion experienced disease progression after 6.6 months of treatment with Truseltiq (infigratinib) and was found to have acquired an FGFR2 L550F mutation (PMID: 34250419). | 34250419 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|